[The use of bone morphogenetic proteins in delayed fracture healing, pseudoarthrosis and in ulna osteotomy carried out because of elbow joint diseases].
This study deals with the application of bone morphogenetic protein (BMP) as an osteoinductive factor in the treatment of fractures and elbow disease in the dog. Partially purified canine bone morphogenetic protein (cBMP) was used in the repair of a delayed union fracture and a pseudoarthrosis. The cBMP was applied in Biocoral and Tricalciumphosphate carriers using a subcortical grafting method. Two dogs suffering from incongruence and subluxation of the elbow joint were treated with a partially purified bone morphogenetic protein of moose bone origin placed in the gap produced by ulnar osteotomy.
Paatsama
S
S
Veterinärmedizinischen Fakultät, Universität Helsinki, Finnland.
Lindholm
S
S
Oksanen
J
J
Axelson
P
P
D000818:Animals; D019485:Bone Morphogenetic Proteins; D001858:Bone Nails / Q000662:veterinary; D001860:Bone Plates / Q000662:veterinary; D001863:Bone Screws / Q000662:veterinary; D002130:Calcium Phosphates; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004337:Drug Carriers; D016267:External Fixators / Q000662:veterinary; D005264:Femoral Fractures / Q000628:therapy / Q000662:veterinary; D005552:Forelimb; D017102:Fracture Healing; D005599:Fractures, Ununited / Q000628:therapy / Q000662:veterinary*; D006133:Growth Substances / Q000008:administration & dosage / Q000627:therapeutic use*; D007592:Joint Diseases / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D004204:Joint Dislocations / Q000601:surgery / Q000628:therapy / Q000662:veterinary; D010027:Osteotomy / Q000662:veterinary*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011542:Pseudarthrosis / Q000628:therapy / Q000662:veterinary*; D011885:Radius Fractures / Q000628:therapy / Q000662:veterinary; D014458:Ulna Fractures / Q000628:therapy / Q000662:veterinary
D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D004337:Drug Carriers; D006133:Growth Substances; D011506:Proteins; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous
Die Anwendung knochenmorphogenetischen Proteins bei verzögerter Frakturheilung, Pseudarthrose und bei wegen Ellbogengelenkerkrankungen durchgeführter Ulnaosteotomie.